Research reveals high-risk subtype of relapsed pediatric AML

For children, young adults with recurrent AML, immunotherapy shows promise

Oncotarget: Fgr and Numb in retinoic differentiation and G0 arrest of non-APL AML cells

Ficlatuzumab plus chemotherapy may benefit patients with relapsed/refractory AML

Oncotarget: Activation of plasmacytoid dendritic cells promotes AML-cell fratricide

Investigational combo therapy shows benefit for TP53 mutant MDS and AML patients

New drug combination shows promise as powerful treatment for AML